Today was the day announced for a decision to be made.
The HSE’s Senior Management Team have approved the reimbursement of Skyclarys for patients with Friedreich’s Ataxia.
Today (25 August) was the day announced for a decision to be made.
HSE senior management met to discuss providing Skyclarys, as Biogen had made a new offer to the Health Service.
The outcome will result in strong engagement with Biogen over the coming years in respect of the treatment of Friedreich’s Ataxia.
The HSE's Drugs Group earlier this month recommended the drug not be reimbursed, over cost-effectiveness concerns.
Skyclarys is the first treatment for the condition, which is shown to slow the symptoms by up to 50pc.
Kfm news had previously spoken to Niamh Ní Hoireabhaird about her experiences with FA, and Craig Coady, a father of two teenage boys have suffered with the disease, one of whom sadly passed away as a result.
The progressive neuro muscular disease causes nerve damage, muscle weakness and mobility loss.
Approximately 200 people are affected by the disease in Ireland.
Charges Dropped Against Asylum Seeker Accused Of Sexual Assault In Saggart Last year
Gardaí Launch Investigation After Body Found In Cork
Ireland Prepares For Winter As Clocks To Go Back This Weekend
Introduction Of Plug-In Solar Panel Technology Approved
Normal People Actors Among Signatures On Letter To UK Government Supporting Sally Rooney
Kildare Saw Significant Increases In Road Deaths This Year
According To New Figures Over 70,000 People Leave ED's Before Finishing Treatment
DART Plus Projects Expected to Progress by End of November
